



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/52874/2014

European Medicines Agency decision

P/0080/2014

of 2 April 2014

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for anti proprotein convertase subtilisin kexin type 9 humanized monoclonal antibody (PF-04950615) (EMA-001430-PIP01-13) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0080/2014

of 2 April 2014

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for anti proprotein convertase subtilisin kexin type 9 humanized monoclonal antibody (PF-04950615) (EMA-001430-PIP01-13) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Pfizer Limited on 14 March 2013 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 14 February 2014, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for anti proprotein convertase subtilisin kexin type 9 humanized monoclonal antibody (PF-04950615), solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for anti proprotein convertase subtilisin kexin type 9 humanized monoclonal antibody (PF-04950615), solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for anti proprotein convertase subtilisin kexin type 9 humanized monoclonal antibody (PF-04950615), solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Pfizer Limited, Ramsgate Road, CT13 9NJ - Sandwich, United Kingdom.

Done at London, 2 April 2014

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/745178/2013

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-001430-PIP01-13

Scope of the application

Active substance(s):

Anti proprotein convertase subtilisin kexin type 9 humanized monoclonal antibody (PF-04950615)

Condition(s):

Treatment of elevated cholesterol

Treatment of mixed dyslipidaemia

Prevention of cardiovascular events in patients with cardiovascular disease or cardiovascular disease risk equivalent

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name / corporate name of the PIP applicant:

Pfizer Limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Pfizer Limited submitted for agreement to the European Medicines Agency on 14 March 2013 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 15 April 2013.

Supplementary information was provided by the applicant on 5 November 2013. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
 - to grant a deferral in accordance with Article 21 of said Regulation;
 - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended occurs only in adult populations; and Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 14 February 2014

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: treatment of elevated cholesterol

The waiver applies to:

- the paediatric population from birth to less than 8 years of age;
- for solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

1.2. Condition: treatment of mixed dyslipidaemia

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- for solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

1.3. Condition: prevention of cardiovascular events in patients with cardiovascular disease or cardiovascular disease risk equivalent

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- for solution for injection, subcutaneous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition: treatment of elevated cholesterol

2.1.1. Indication(s) targeted by the PIP

Treatment of heterozygous or homozygous familial hypercholesterolemia.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 8 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Solution for injection.

2.1.4. Measures

Area	Number of studies	Description
Quality-related studies	1	Study 1: Development of a pre-filled syringe or pre-filled pen.
Non-clinical studies	0	Not applicable.
Clinical studies	2	Study 2: Open-label study to evaluate the pharmacokinetics, safety and activity of anti proprotein convertase subtilisin kexin type 9 humanized monoclonal antibody (PF-04950615), as add-on to stable lipid lowering therapy, in children from 8 to less than 18 years of age with heterozygous or homozygous familial hypercholesterolaemia. Study 3: Double-blind, randomised, placebo-controlled trial to evaluate the safety and efficacy of anti proprotein convertase subtilisin kexin type 9 humanized monoclonal antibody (PF-04950615), as add-on to stable lipid lowering therapy, in children from 8 to less than 18 years of age with heterozygous or homozygous familial hypercholesterolaemia, with primary efficacy assessment at 6 months followed by an open label extension for a total duration of 2 years.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2023
Deferral for one or more measures contained in the paediatric investigation plan:	Yes